Suppression of transplant rejection
AssigneeIsis Innovation Limited
InventorsAndrew Bushell, Kathryn Wood, Mahzuz Karim, Vanessa Oliveira, Brigit Sawitzki
Life of this patent
Estimating the term…
Loading patent…
AssigneeIsis Innovation Limited
InventorsAndrew Bushell, Kathryn Wood, Mahzuz Karim, Vanessa Oliveira, Brigit Sawitzki
Estimating the term…
The present invention relates to a transplant rejection in an animal suppressed by administration of an antibody directed at a cell surface antigen selected from the group consisting of CD4, CD8, CD154, LFA-1, CD80, CD86 and ICAM-1, preferably an anti-CD4 antibody, together with a non-cellular protein antigen to generate in the animal a population of regulatory T-lymphocytes; reactivating said population of regulatory T-lymphocytes by further administration to the animal of the non-cellular protein antigen; and transplanting said organ or tissue whilst said population of regulatory T-lymphocytes is activated. Regulatory T cells can be generated ex vivo by culturing T cells with an antibody directed at a cell surface antigen selected from the group consisting of CD4, CD8, CD154, LFA-1, CD80, CD86 and ICAM-1, in the presence of cells that present either alloantigen or a non-cellular protein antigen. Ex vivo generated T-lymphocytes can be used as an alternative method of overcoming transplant rejection or in combination with the in vivo method. A similar approach can be adopted for the treatment of autoimmune conditions.
1-59. (canceled)
A method of treating a condition in an animal mediated by an immune response which comprises administering to said animal an antibody directed at a cell surface antigen selected from the group consisting of CD4, CD8, CD 154, LFA-1, CD80, CD86 and ICAM-1, and a non-cellular protein antigen to generate a population of regulatory T-lymphocytes.
An ex vivo method for generating a population of regulatory T lymphocytes comprising culturing T cells with an antibody directed at a cell surface antigen selected from the group consisting of CD4, CD8, CD154, LFA-1, CD80, CD86 and ICAM-1 in the presence of cells that present either alloantigen or a non-cellular protein antigen.
A method of suppressing rejection of an organ or tissue transplant in a recipient animal comprising the following steps:
Dependencies are inferred from the claim text.